Cargando…

A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

AIMS/HYPOTHESIS: Numerous clinical studies have investigated the anti-CD3ɛ monoclonal antibody otelixizumab in individuals with type 1 diabetes, but limited progress has been made in identifying the optimal clinical dose with acceptable tolerability and safety. The aim of this study was to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keymeulen, Bart, van Maurik, André, Inman, Dave, Oliveira, João, McLaughlin, Rene, Gittelman, Rachel M., Roep, Bart O., Gillard, Pieter, Hilbrands, Robert, Gorus, Frans, Mathieu, Chantal, Van de Velde, Ursule, Wisniacki, Nicolas, Napolitano, Antonella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801303/ https://www.ncbi.nlm.nih.gov/pubmed/33145642 http://dx.doi.org/10.1007/s00125-020-05317-y

Ejemplares similares

Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes
por: Demeester, Simke, et al.
Publicado: (2015)

Minimal Functional β-Cell Mass in Intraportal Implants That Reduces Glycemic Variability in Type 1 Diabetic Recipients
por: Gillard, Pieter, et al.
Publicado: (2013)

Graves Hyperthyroidism After Stopping Immunosuppressive Therapy in Type 1 Diabetic Islet Cell Recipients With Pretransplant TPO Autoantibodies
por: Gillard, Pieter, et al.
Publicado: (2009)

Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 Diabetes
por: van der Torren, Cornelis R., et al.
Publicado: (2016)

Cellular Islet Autoimmunity Associates with Clinical Outcome of Islet Cell Transplantation
por: Huurman, Volkert A. L., et al.
Publicado: (2008)

Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic Patients
por: Hilbrands, Robert, et al.
Publicado: (2009)

CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients
por: Vandewalle, Julie, et al.
Publicado: (2023)

Genetic variation at ERBB3/IKZF4 and sexual dimorphism in epitope spreading in single autoantibody-positive relatives
por: Vandewalle, Julie, et al.
Publicado: (2021)

Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio
por: Van Dalem, Annelien, et al.
Publicado: (2016)

Correction: Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio
por: Van Dalem, Annelien, et al.
Publicado: (2017)

Utility of Islet Cell Preparations From Donor Pancreases After Euthanasia
por: De Paep, Diedert L., et al.
Publicado: (2022)

Where, How, and When: Positioning Posttranslational Modification Within Type 1 Diabetes Pathogenesis
por: McLaughlin, Rene J., et al.
Publicado: (2016)

Insulitis in the pancreas of non-diabetic organ donors under age 25 years with multiple circulating autoantibodies against islet cell antigens
por: Smeets, Silke, et al.
Publicado: (2021)

Potential of Protein Phosphatase Inhibitor 1 As Biomarker of Pancreatic β-Cell Injury In Vitro and In Vivo
por: Jiang, Lei, et al.
Publicado: (2013)

Contribution of Antibodies Against IA-2β and Zinc Transporter 8 to Classification of Diabetes Diagnosed Under 40 Years of Age
por: Vermeulen, Ilse, et al.
Publicado: (2011)

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
por: de Filette, Jeroen M K, et al.
Publicado: (2019)

The MicroRNA Landscape of Acute Beta Cell Destruction in Type 1 Diabetic Recipients of Intraportal Islet Grafts
por: Martens, Geert A., et al.
Publicado: (2021)

β-Cells, Autoimmunity, and the Innate Immune System: “un Ménage á Trois”?
por: Roep, Bart O.
Publicado: (2013)

There Is Something About Insulin Granules
por: Roep, Bart O.
Publicado: (2020)

The need and benefit of immune monitoring to define patient and disease heterogeneity, mechanisms of therapeutic action and efficacy of intervention therapy for precision medicine in type 1 diabetes
por: Roep, Bart O.
Publicado: (2023)

Regulatory Multitasking of Tolerogenic Dendritic Cells – Lessons Taken from Vitamin D3-Treated Tolerogenic Dendritic Cells
por: Nikolic, Tatjana, et al.
Publicado: (2013)

Islet-Resident Dendritic Cells and Macrophages in Type 1 Diabetes: In Search of Bigfoot’s Print
por: Zirpel, Henner, et al.
Publicado: (2021)

Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)
por: Roep, Bart O., et al.
Publicado: (2020)

Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial
por: Piemonti, Lorenzo, et al.
Publicado: (2022)

Low risk for diabetic complications in type 1 diabetes patients carrying a protective insulin gene variant
por: van Tienhoven, René, et al.
Publicado: (2023)

Artificial intelligence: is there a potential role in nephropathology?
por: Hermsen, Meyke, et al.
Publicado: (2020)

Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials
por: Suwandi, Jessica S., et al.
Publicado: (2017)

Islet stress, degradation and autoimmunity
por: Thomaidou, Sofia, et al.
Publicado: (2018)

Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders
por: Sordi, Valeria, et al.
Publicado: (2023)

Simultaneous Detection of Circulating Autoreactive CD8(+) T-Cells Specific for Different Islet Cell–Associated Epitopes Using Combinatorial MHC Multimers
por: Velthuis, Jurjen H., et al.
Publicado: (2010)

A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2018)

From Disease and Patient Heterogeneity to Precision Medicine in Type 1 Diabetes
por: den Hollander, Nicoline H. M., et al.
Publicado: (2022)

ConTra: a promoter alignment analysis tool for identification of transcription factor binding sites across species
por: Hooghe, Bart, et al.
Publicado: (2008)

A distance difference matrix approach to identifying transcription factors that regulate differential gene expression
por: De Bleser, Pieter, et al.
Publicado: (2007)

A flexible integrative approach based on random forest improves prediction of transcription factor binding sites
por: Hooghe, Bart, et al.
Publicado: (2012)

Use of phage display technology for the selection of monoclonal antibodies in allergen research and diagnostics
por: Vandekerckhove, Marjolein, et al.
Publicado: (2014)

Self-Glycolipids Modulate Dendritic Cells Changing the Cytokine Profiles of Committed Autoreactive T Cells
por: Buschard, Karsten, et al.
Publicado: (2012)

Functional Impact of Risk Gene Variants on the Autoimmune Responses in Type 1 Diabetes
por: Gootjes, Chelsea, et al.
Publicado: (2022)

In vivo affinity and target engagement in skin and blood in a first‐time‐in‐human study of an anti‐oncostatin M monoclonal antibody
por: Reid, Juliet, et al.
Publicado: (2018)

Characterization of N-Terminal Asparagine Deamidation and Clipping of a Monoclonal Antibody
por: Zhen, Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vlnu1spisqn3mm4aveddntdsjn